Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Common Equity (2016 - 2025)

Historic Common Equity for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $54.3 million.

  • Marimed's Common Equity fell 1992.9% to $54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.3 million, marking a year-over-year decrease of 1992.9%. This contributed to the annual value of $58.5 million for FY2024, which is 1625.85% down from last year.
  • Latest data reveals that Marimed reported Common Equity of $54.3 million as of Q3 2025, which was down 1992.9% from $58.4 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Common Equity peaked at $80.9 million during Q2 2023, and registered a low of $14.7 million during Q1 2021.
  • Over the past 5 years, Marimed's median Common Equity value was $58.4 million (recorded in 2025), while the average stood at $54.9 million.
  • As far as peak fluctuations go, Marimed's Common Equity surged by 4199492.53% in 2021, and later crashed by 1992.9% in 2025.
  • Over the past 5 years, Marimed's Common Equity (Quarter) stood at $36.3 million in 2021, then skyrocketed by 57.88% to $57.3 million in 2022, then rose by 21.99% to $69.9 million in 2023, then decreased by 16.26% to $58.5 million in 2024, then fell by 7.22% to $54.3 million in 2025.
  • Its Common Equity was $54.3 million in Q3 2025, compared to $58.4 million in Q2 2025 and $59.2 million in Q1 2025.